Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8359144 | Prostaglandins & Other Lipid Mediators | 2017 | 9 Pages |
Abstract
This paper provides a comprehensive overview of the literature on PUFAs in AN. We also selectively reviewed the clinical benefits PUFA treatments exert in other psychiatric diseases, on weight and appetite regulation, and for resolution of inflammation, all of which are relevant in the disease course and outcome of AN. We propose that personalized PUFA formulation be developed and tested as a novel adjunctive treatment for patients with AN. We hypothesize that with personalized PUFA formulation, food aversion and anxiety about eating will decrease while mood, dietary behavior, and weight restoration will improve in AN, leading to improvements in the overall treatment outcome.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biochemistry
Authors
P. Betty Shih, Christophe Morisseau, Thu Le, Blake Woodside, J. Bruce German,